SOX2 Expression Does Not Guarantee Cancer Stem Cell-like Characteristics in Lung Adenocarcinoma

• Published in: Cells (Basel, Switzerland) Vol. 13; no. 3; p. 216
• Main Authors: Bae, Seung-Hyun, Lee, Kyung Yong, Han, Suji, Yun, Chul Won, Park, ChanHyeok, Jang, Hyonchol
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.01.2024
• Subjects: Adenocarcinoma; cancer stem cell-like properties; Cancer therapies; Care and treatment; CRISPR; CRISPR/Cas9; Flow cytometry; Gene amplification; Genetic aspects; lung adenocarcinoma; Lung cancer; Lung cancer, Non-small cell; Malignancy; Medical prognosis; Monoclonal antibodies; Mutagenesis; Physiological aspects; Plasmids; Pluripotency; shRNA; siRNA; SOX2; Sox2 protein; Stem cell factor; Stem cells; Transcription factors; Tumors; South Korea; United States > US; SOX2; CRISPR/Cas9; shRNA; cancer stem cell-like properties; lung adenocarcinoma
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells13030216

Effectively targeting cancer stemness is essential for successful cancer therapy. Recent studies have revealed that , a pluripotent stem cell factor, significantly contributes to cancer stem cell (CSC)-like characteristics closely associated with cancer malignancy. However, its contradictory impact on patient survival in specific cancer types, including lung adenocarcinoma (LUAD), underscores the need for more comprehensive research to clarify its functional effect on cancer stemness. In this study, we demonstrate that is not universally required for the regulation of CSC-like properties in LUAD. We generated knockouts in A549, H358, and HCC827 LUAD cells using the CRISPR/Cas9 system. Our results reveal unchanged CSC characteristics, including sustained proliferation, tumor sphere formation, invasion, migration, and therapy resistance, compared to normal cells. Conversely, knockdown using conditional shRNA targeting , significantly reduced CSC traits. However, these loss-of-function effects were not rescued by resistant to shRNA, underscoring the potential for SOX2 protein level-independent results in prior siRNA- or shRNA-based research. Ultimately, our findings demonstrate that is not absolutely essential in LUAD cancer cells. This emphasizes the necessity of considering cancer subtype-dependent and context-dependent factors when targeting overexpression as a potential therapeutic vulnerability in diverse cancers.